<DOC>
	<DOCNO>NCT01499303</DOCNO>
	<brief_summary>This study evaluate effectiveness fostamatinib ( 200 mg twice day ) patient worsen unmanageable lymphoma specific type lymphoma call Diffuse Large B-Cell Lymphoma ( abbreviate DLBCL )</brief_summary>
	<brief_title>Study Learn 200mg Test Drug ( Fostamatinib ) Helps People With Large B-Cell Lymphoma , Type Blood Cancer</brief_title>
	<detailed_description>Phase II Trial Evaluate Efficacy Fostamatinib Patients Relapsed Refractory Diffuse Large B-Cell Lymphoma ( DLBCL )</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>Aged least 18 year age . Patients relapse refractory diffuse large Bcell lymphoma previously receive RCHOP ( equivalent ) chemoimmunotherapy high dose chemotherapy stem cell rescue , ineligible high dose therapy stem cell rescue . Measurable disease define Cheson et al 2007 criterion . One fresh pretreatment excisional core needle biopsy suitable accessible site . World Health Organization ( WHO ) performance status 0 1 . Treatment nitrosurea , mitomycin C , investigational agent study drug w/in28 day first dose study treatment , chemotherapy , immunotherapy anticancer agent w/in 3 week first dose study treatment , previous fostamatinib . With exception alopecia , unresolved toxicity prior therapy surgery great Common Terminology Criteria Adverse Events ( CTCAE ) Grade 1 . Uncontrolled hypertension ( define &gt; 140mmHg systolic and/or &gt; 90 mmHG diastolic baseline without antihypertensive therapy . Evidence tuberculosis ( TB ) . Inadequate boen marrow reserve .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>lymphoma</keyword>
	<keyword>DLBCL</keyword>
	<keyword>fostamatinib</keyword>
	<keyword>Diffuse Large B-Cell Lymphoma ( DLBCL )</keyword>
</DOC>